Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul 20;38(21):2467-2468.
doi: 10.1200/JCO.20.00833. Epub 2020 May 14.

Reply to N. Fazio

Eileen M O'Reilly  1 , Wungki Park  1 , David P Kelsen  1
Affiliations
Comment

Reply to N. Fazio

Eileen M O'Reilly et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Fazio N. Cisplatin plus gemcitabine as standard of care for germline BRCA/PALB2-mutated pancreatic adenocarcinoma: Are we moving too fast? J Clin Oncol. 2020;38:2466–2467. - PubMed
    1. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat Med. 2018;24:628–637. - PMC - PubMed
    1. Lohse I, Borgida A, Cao P, et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113:425–432. - PMC - PubMed
    1. Pishvaian MJ, Blais EM, Brody JR, et al. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program. JCO Precis Oncol. 10.1200/PO.19.00115 - DOI - PubMed
    1. Park W, Wong W, Yu KH, et al. Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC) J Clin Oncol 372019suppl; abstr 4132)